The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

OBJECTIVES: Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the effectiveness of sofosbuvir in combination with...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Eslami, Gholamali, Mousaviasl, Sajedeh, Radmanesh, Esmat, Jelvay, Saeed, Bitaraf, Saeid, Simmons, Bryony, Wentzel, Hannah, Hill, Andrew, Sadeghi, Anahita, Freeman, James, Salmanzadeh, Shokrollah, Esmaeilian, Hani, Mobarak, Morteza, Tabibi, Ramin, Jafari Kashi, Amir Hosein, Lotfi, Zahra, Talebzadeh, Seyed Mehdi, Wickramatillake, Aseni, Momtazan, Mahboobeh, Hajizadeh Farsani, Majid, Marjani, Sedigheh, Mobarak, Sara
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7529105/
https://ncbi.nlm.nih.gov/pubmed/32812051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkaa331
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi